Author: Ascelia Pharma

Posted Date:

April 9, 2026

Annual Report 2025: Orviglance NDA submitted to the FDA, PDUFA-date set for July 2026

Ascelia Pharma

April 9, 2026
Notice of Annual General Meeting in Ascelia Pharma AB

Ascelia Pharma

March 30, 2026
Ascelia Pharma Announces Acceptance of Orviglance Data for Oral Presentation at the Annual Radiology Congress ESGAR 2026

Ascelia Pharma

March 27, 2026
Full Year and Q4 Report 2025: FDA Accepts Orviglance NDA for Review

Ascelia Pharma

February 7, 2026